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Cholinergic dysfunction plays a critical role in a number of disease states, and the loss 
of functional muscarinic acetylcholine receptors plays a key role in disease 
pathogenesis.  Therefore, preventing receptor downregulation would maintain 
functional receptor number, and be predicted to alleviate symptoms.  However, the 
molecular mechanism(s) underlying muscarinic receptor downregulation are currently 
unknown.  Here we demonstrate that the M2 muscarinic receptor undergoes rapid 
lysosomal proteolysis, and this lysosomal trafficking is facilitated by ubiquitination of 
the receptor.  Importantly, we show that this trafficking is driven specifically by ESCRT 
mediated involution.  Critically, we provide evidence that disruption of this process 
leads to a re-routing of the trafficking of the M2 receptor away from the lysosome and 
into recycling pathway, and eventually back to the plasma membrane.  This study is 
the first to identify the process by which the M2 muscarinic receptor undergoes 
endocytic sorting, and critically reveals a regulatory checkpoint that represents a target 
to pharmacologically increase the number of functional muscarinic receptors within the 












Cholinergic dysfunction is critical in the pathophysiology of various disorders including 
Alzheimer’s, Parkinson’s, schizophrenia and addiction, and, an understanding into 
how the cholinergic system is regulated, is of vital importance for the identification of 
therapeutic targets (Felder et al., 2000; Langmead et al., 2008; McKinzie and 
Bymaster, 2012; Wess et al., 2007).  Central to the regulation of the cholinergic system 
are the muscarinic family of acetylcholine receptors (mAChRs1), M1-5, the activation 
of which plays a critical modulatory role within the central nervous system (CNS) 
(Lebois et al., 2018; Levey, 1996).  Disruption of mAChR function can result in range 
of pathophysiological effects, both peripherally and within the CNS (Kruse et al., 2014; 
Thomsen et al., 2018; Wess et al., 2007). Accordingly, a reduction in functional 
mAChR receptor number has been observed in patients with Alzheimer’s disease, 
bipolar disorder, schizophrenia and psychosis (Gibbons et al., 2016, 2013; Scarr, 
2012; Scarr et al., 2018).  Despite its undoubted importance, little is known regarding 
the mechanisms regulating the receptor number of mAChR. 
All five mAChRs belong to the G-protein-coupled receptor (GPCR) family of 
membrane proteins (Kruse et al., 2014; Lebois et al., 2018).  One important 
mechanism by which the levels of functional GPCR are maintained is by endocytic 
trafficking, and the sorting of these receptors to the lysosome for proteolysis and 
downregulation, preventing overstimulation.  It is now well established that mAChRs, 
like other GPCRs, undergo extensive endocytic trafficking followed by downregulation 
in the face of excess activation (Bernard et al., 2003, 1999; Decossas et al., 2005; 
Thangaraju and Sawyer, 2011), however, the molecular mechanisms responsible for 
this process remain broadly unknown (Reiner and Nathanson, 2012; Zenko and 
Hislop, 2018).   
The established model for the regulation of GPCRs involves agonist activated 
receptors first being uncoupled from the G-protein (desensitization) by a combination 
of phosphorylation (mediated by G-protein Receptor kinases) and interaction with 
                                                          
1 Abbreviations: AlexFluor – AF, CNS – Central Nervous System, DRG - Dorsal Root 
Ganglia, EEA1 - Early Endosome Antigen 1, ESCRT - Endosomal Sorting Complex Required for 
Transport, GPCR - G-Protein-Coupled-Receptor, HEK 293 - Human Embryonic Kidney 293 cell line, 
LAMP1 - lysosomal associated membrane protein 1, M2R - muscarinic receptor 2, mAChR - muscarinic 




arrestins (Ferguson, 2001; Krupnick and Benovic, 1998; Pierce et al., 2001).  
Desensitized receptors are then removed from the plasma membrane to prevent 
further activation by ligands (Hanyaloglu and von Zastrow, 2008; Sorkin and Von 
Zastrow, 2002). Following internalization into the endocytic pathway, GPCRs, like 
other membrane cargo, can either undergo recycling back to the plasma membrane 
leading to functional resensitization, or are transported to the lysosome for proteolysis 
and long-term downregulation (Eden et al., 2012; Hanyaloglu and von Zastrow, 2008; 
Hislop and von Zastrow, 2011; Zenko and Hislop, 2018).  Central to lysosomal 
targeting is the regulatory protein ubiquitin.  Sorting of membrane cargo including the 
GPCR Ste2p (Hicke and Riezman, 1996) to the lysosome/vacuole has been 
extensively studied in the yeast model system, and also in mammalian cells (Dunn 
and Hicke, 2001; Haglund and Dikic, 2012; Wendland et al., 1998). The covalent 
attachment of ubiquitin and polyubiquitin chains to the cytoplasmic portion of 
membrane proteins, such as the epidermal growth factor receptor (EGFR), prevents 
recycling and targets the receptor to the lumen of the endosome by a process termed 
involution (Katzmann et al., 2002; Raiborg and Stenmark, 2009; Saksena et al., 2007; 
Schoneberg et al., 2017).  These larger, more spherical endosomes, known as 
multivesicular bodies, have a number of receptor containing intraluminal vesicles that 
can now be exposed to lipases and proteases upon fusion with the lysosome leading 
to proteolysis and long term downregulation of the receptor.  Involution and lysosomal 
sorting are driven by the interaction of the ubiquitinated cargo with a complex of 
proteins collectively known as the Endosomal Sorting Complex Required for Sorting 
(ESCRT), thus ubiquitin regulates both the sorting and subsequent proteolysis of these 
membrane receptors (Katzmann et al., 2002; Raiborg et al., 2003; Razi and Futter, 
2006).  For GPCRs, however, the role of ubiquitination is far less clear, with some 
receptors requiring ubiquitination, some having no requirement for ubiquitination, and 
other GPCRs utilising ubiquitin for proteolysis, but not for actively sorting the receptor 
to the lysosome.  (Hislop and von Zastrow, 2011; Marchese and Trejo, 2013; 
Skieterska et al., 2017). Importantly, the role of ubiquitination and the mechanism(s) 
responsible for lysosomal sorting of the mAChR has not been investigated 
Although the early endocytic events have been previously investigated for the 
muscarinic receptors (Gurevich et al., 1995; Hosey et al., 1999; Pals-Rylaarsdam et 
al., 1997; Schlador and Nathanson, 1997; van Koppen, 2001), the post-endocytic fate 
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of this important group of receptors has been largely overlooked. Here we investigated 
the mechanisms responsible for the post-endocytic sorting and downregulation of a 
typical mAChR, the M2 mAChR (M2R), whose downregulation is physiologically 
relevant.  Using a number of complimentary biochemical and imaging techniques, we 
clearly show that both receptor ubiquitination and the ESCRT machinery are required 
for M2R downregulation.  Importantly, we also demonstrate that, in contrast to a 
number of GPCRs, direct ubiquitination is also the prime mechanism for sorting the 
M2R to the lysosome, and preventing recycling.  The identification of the molecular 
checkpoint responsible for regulating surface receptor number of M2R represents an 
important target for the development of therapeutics designed to increase receptor 
expression and function. 
2. Methods 
2.1 Antibodies and Reagents 
Functionally verified siRNA oligos were  purchased from Qiagen (AllStars Negative 
Control, HRS (Hs_HGS_6 Flexitube siRNA), Tsg101 (Hs_TSG101_7 Flexitube 
siRNA), antibody against Flag (M1 clone) was purchased from Sigma and labelled 
with AlexaFluor (AF) 488, 568 or 647 fluorophores using AlexaFluor antibody labelling 
kit according to manufacturer’s instructions (ThermoFisher). 
2.2 Cell Culture, Constructs and Transfection 
DNA of the coding region of the M2 muscarinic receptor (M2R) was purchased from 
Missouri S&T cDNA resource centre.  The M2R-0cK (M2R with all intracellular lysine 
residues mutated to arginine) was synthesised by GeneArt (ThermoFisher).  All 
constructs were amplified by PCR and ligated into N terminally tagged SS-Flag and 
SS-HA vectors (a gift from Prof. Mark von Zastrow, University of California, San 
Francisco UCSF)).  For expression in dorsal root ganglion neurons (DRGs), PCR was 
used to amplify the SSF-M2R and SSF-M2R-0cK and subcloned into pCAGGS 
neuronal expression vector (a gift from Prof. Mark von Zastrow, UCSF (Kotowski et 
al., 2011)).  To tag receptors in-frame with superecliptic GFP, cDNA of SSF-M2 and 
SSF-M2-0cK were amplified by PCR to remove the stop codon and add an AgeI 
restriction site.  PCR products were then subcloned into the previously described 
vector (Henry et al., 2011). LAMP1-RFP was a gift from Walther Mothes (Addgene 
plasmid #1817; http://n2t.net/addgene:1817 ; RRID:Addgene_1817 (Sherer et al., 
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2003)), EGFP-β-Arr1, EGFP-β-Arr2, and EGFP-RAB5 were kind gifts from Prof. Mark 
von Zastrow, UCSF. EGFP-Rab11 and EGFP Rab7 was a kind gift from Dr. Rey 
Carabeo (Washington State University).  
Human embryonic 293 (HEK 293) cells were cultured in Dubecco’s modified eagle 
medium (DMEM) supplemented with 10% heat inactivated foetal bovine serum (FBS) 
and routinely passaged by lifting in PBS-EDTA.  All transfections were carried out 
using Lipofectamine 2000 according to manufacturer instructions, unless otherwise 
stated.  Cells were transfected in 6-well plates and then replated onto poly-L-lysine 
coated glass coverslips.  Transfection of RNAi was achieved by the use of 
Lipofectamine RNAiMax according to manufacturer instructions as previously 
described (Hislop et al., 2009).  HEK 293 cells stably expressing Flag-epitope tagged 
receptors were created by transfection of cDNA and selection in zeocin.  Clones were 
screened for stable expression by immunofluorescent staining and Western Blotting. 
2.3 Calcium phosphate transfection for detection of ubiquitin. 
For ubiquitination assay, M2R or M2R-0cK HEK 293 cells were grown to ~50% 
confluency in 60mm dishes and transfected using a calcium phosphate transfection 
method. For each plate, 1 µg of HA-ubiquitin was dissolved in 300 µl of 25 mM CaCl2. 
The DNA:CaCl2 solution was then added dropwise (while slowly mixing to ensure 
precipitate formation) to an equal volume (300 µl) of 2 x HBS buffer (50 mM HEPES, 
280 mM NaCl, 1.5 mM Na2HPO4, pH 7.0), mixed and incubated at room temperature 
for 30 minutes to allow precipitation. The mixture was then added dropwise to the 
dishes and incubated for 48 hours before experimentation. 
2.4 Culture and transfection of dorsal root ganglia 
All animal procedures were approved by the local Ethics Committee and performed in 
accordance with the United Kingdom Animals Scientific Procedures Act (1986) and 
associated guidelines. 
DRG neurons were obtained from postnatal (P1-P2) Sprague-Dawley (SD) rats. 
Following schedule 1 (cervical dislocation followed by decapitation) spinal cords were 
carefully removed, cut through the vertebral column and DRGs were isolated one at a 
time using fine forceps. DRGs were incubated in the 0.025% trypsin/EDTA (Sigma-
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Aldrich) for 20 minutes at 37°C following mechanic dissociation of the ganglia by 
triturating using a 1ml glass fire-polished pipette.  
The cell suspension was then passed through a cell strainer (Cole-Parmer), collected 
into 50 mL centrifuge tube followed by centrifugation at 500 x g for 5 minutes. Cells 
were resuspended in pre-warmed neurobasal medium (Gibco) supplemented with B27 
(Gibco), 1% penicillin-streptomycin (Sigma-Aldrich), 5.0 μg/mL insulin from bovine 
pancreas powder (Sigma-Aldrich), 1% GlutaMax (Gibco) and 50 ng/mL β-NGF (BD 
Biosciences). DRG neurons were then plated (70,000 cells/well) onto poly-L-lysine- 
and 20 ng/mL laminin- coated 12 mm coverslips and maintained for one week with 
half-volume of the media being replaced every 2 days.  
For transfections, cells were centrifuged at 500 x g for 5 minutes and resuspended in 
pre-equilibrated room temperature Nucleofector® solution (100 μL per 2 x 106 cells 
per transfection), combined with 2 μg of plasmid DNA (M2R:pCAGGS or M2R-
0cK:pCAGGS) and electroporated (Nucleofector II, program G-013, Amaxa Lonza). 
Cells were immediately placed into pre-warmed HBSS for 10 minutes before 
resuspension in Neurobasal media and plated onto coverslips as described above. 
2.5 Biochemical detection of receptor proteolysis and protein levels by immunoblotting 
Total cellular levels of protein were determined by immunoblotting as previously 
described (Hislop et al., 2004).  Briefly, cells were plated into 12-well culture plates 
and treated as described in figure legends before washing in ice-cold PBS and lysing 
in extraction buffer (0.5% Triton X-100, 150 mM NaCl, 25 mM KCl, 25 mM Tris pH 7.4, 
1 mM EDTA) supplemented with a standard protease inhibitor cocktail (Roche).  
Lysates were clarified by centrifugation and resolved by SDS-PAGE using an 8% 
acrylamide gel and transferred to nitrocellulose and detected using horseradish 
peroxidase-conjugated sheep anti-mouse IgG (Amersham Biosciences) or donkey 
anti-rabbit IgG (Sigma) and enhanced chemiluminesence (ECL) prime detection 
reagent (Amersham). Band intensities of unsaturated immunoblots were analysed 
using Peqlab software and quantified by densitometry on ImageJ. 
2.6 Biotin Protection Degradation Assay  
The fate of the surface, mature pool of receptors was determined by surface 
biotinylation as previously described (Thompson et al., 2014). Cells plated in 60mm 
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dishes were labelled for 30 mins at 4°C with 30 μg/ml disulfide-cleavable biotin 
(ThermoPierce), washed in Tris Buffered saline (TBS) and all but the 100% and strip 
plates (which were kept at 4°C until the end of the experiment) were incubated in 5 ml 
culture medium at 37°C for 15 mins before stimulation with 10 µM carbachol for 30, 
90, or 180 min. Subsequently, all plates (except the 100%) were then washed (2 x 
PBS), stripped to remove remaining surface-biotin (50 μM glutathione, 0.3 mM NaCl, 
75 mM NaOH, 1% FBS, 2 x 10 min, 4oC), quenched (PBS containing 1 mM 
iodoacetamide, 0.1% BSA, 10 min, 4oC), and then lysed in immunoprecipitation buffer 
(150 mM NaCl, 25 mM KCl, 10 mM Tris-HCl, pH 7.4, 0.1% Triton X-100, and protease 
inhibitors). Lysates were immunoprecipitated (anti-FLAG M2) overnight and incubated 
for 2 h with recombinant protein G-Sepharose (Life Technologies) and deglycosylated 
using PNGaseF. Samples were then resolved by SDS-PAGE and visualised with 
streptavidin overlay (VECTASTAIN ABC immunoperoxidase reagent, Vector 
Laboratories). 
2.7 Receptor downregulation by radioligand binding 
Receptor down-regulation was determined by radioligand binding as previously 
described (Thangaraju and Sawyer, 2011). HEK 293 cells stably expressing FLAG-
tagged receptors were re-plated into 12-well plates. 24 h later 10 μM Carbachol was 
added to the cells for the indicated time period, cells were washed twice with ice-cold 
PBS, and 300 μl of PBS was added to the cells, and the plates were frozen. Plates 
were thawed, and cells passed through a 22G needle. Binding assays were performed 
in triplicate in 96-well plates with 15 nM [3H] quinuclidinyl benzilate (QNB) (Perkin 
Elmer, 32.9 Ci/mmol), incubated for 3 h at 4oC. Incubations were terminated by 
vacuum filtration through glass fiber filters (Whatman), and repeated washes with TBS. 
Bound radioactivity was determined by liquid scintillation counting of washed filters. 
Nonspecific binding, determined by carrying out parallel determinations in the 
presence of excess unlabeled competitive antagonist (10 μM atropine), was <10% of 
specific activity added. 
2.8 Live Cell Imaging using the pH-sensitive GFP variant 
Involution was determined by live imaging of C-terminal tagged pH-sensitive GFP as 
previously described (Henry et al., 2011). Briefly, HEK 293 cells were transiently-
transfected with the constitutively active mCherry-Rab5-Q79L and the indicated N-
9 
 
terminally FLAG-tagged, C-terminally ecliptic GFP variant-tagged receptor constructs 
and plated onto polylysine-coated glass coverslips. Cells were incubated in the 
presence of 10 µM Carbachol for 90 min prior to imaging. Cells were imaged with an 
Ultra VIEW VoX spinning disc confocal microscope (Perkin Elmer) for 30s and then 
500 µM chloroquine was added to cells while image acquisition continued for an 
additional 5 minutes with one frame taken every 5 seconds. Cross-sections showing 
chloroquine-induced appearance inside endosomal lumen were analysed using 
Volocity software. Raw data was exported to TIFF (16-bit) format and mean 
fluorescence intensities of individual endosomes before and after chloroquine 
treatment were measured using ImageJ software. Briefly, selections were drawn 
around each endosome and the mean fluorescence values were background 
corrected. Background subtracted fluorescence intensities obtained from first ten 
frames of image sequence were averaged and identified as the “minimum 
fluorescence value”. The maximum average fluorescence value was determined from 
the last ten frames of the acquired image sequence. The fold increase for each 
endosome was determined from the average maximum fluorescence value was 
divided by the average minimum fluorescence value.  
2.9 Laser-scanning confocal microscopy of fixed specimens 
HEK 293 cells were transiently transfected with either F-M2R or F-M2R-0cK and then 
plated on polylysine-coated glass coverslips. In some experiments, cells were co-
transfected with, Rab7 or Rab11, GFP-HRS or GFP-TfnR.  Cells were fed M1-563 
anti-FLAG antibody for 30 minutes at 37°C before being treated with agonist for the 
indicated times and fixation with 4% formaldehyde in PBS.  Fixation was quenched 
with TBS for 10 minutes before mounting or further processing.  To label intracellular 
compartments, cells were permeablised and blocked (TBS, 0.1% Triton-X100, 3% 
BSA) for 30 minutes before incubation with antibody against EEA1 (1/200), or Rab11 
(1/200) overnight at 4°C.  Finally, cells were incubated with AF-488 labelled secondary 
(1/2000) for 1 hour at room temperature, before mounting on microscope slides for 
analysis by confocal fluorescence microscopy using a Zeiss LSM 710 microscope 
fitted with a Zeiss 63 x NA1.4 objective operated in single photon mode, with standard 
filter sets verified for lack of detectable cross-channel bleed through and standard (1 
Airy disc) pinhole. Acquired optical sections were rendered using a 2 pixel median filter 
and the contrast enhanced equally across the whole image, before analysis with 
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ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018).  Colocalization was quantified 
by Manders’ coefficient using thresholds using the JaCOP plugin (Bolte and 
Cordelieres, 2006). All experiments were repeated on 3-4 independent occasions, and 
colocalization determined on a cell by cell basis. 
2.10 Measurement of recycling by Flow Cytometry  
Recycling of Flag-tagged M2R or M2R-0cK was determined by flow cytometry as 
previously described (Thompson et al., 2014). Surface receptors were labelled with 
the calcium sensitive antibody anti-Flag M1 conjugated to AF647 (1:1,000) for 30 min, 
before stimulation with carbachol for 30 min. Following stimulation, cells were rapidly 
washed with PBS/EDTA (2 mM) to remove any surface antibody and either 
resuspended in PBS (containing Ca2+ and Mg2+) to measure endocytosis (as 
indicated by an increase in fluorescence due to internalization protecting from the 
PBS/EDTA wash) or returned to the incubator in the presence of PBS/EDTA to 
measure recycling (as determined by a loss of fluorescence over time). Following all 
treatments, cells were pelleted, washed, and resuspended in PBS (containing Ca2+ 
and Mg2+). All time points were prepared in duplicate, and samples were analysed 
using a FACSCalibur (BD Biosciences) with 5,000 events being analysed in all cases.  
2.11 Ratiometric analysis of internalization and recycling 
Internalization and recycling of transfected DRG neurons was measured as previously 
described (Kotowski et al., 2011; Tanowitz and von Zastrow, 2003; Yu et al., 2010).  
Briefly, cells were plated onto poly-lysine coated coverslips and 48 hours later were 
incubated with anti-Flag M1 conjugated to AF-488 before agonist treatment.  Cells 
were then fixed in freshly made 4% paraformaldehyde in PBS (100%).  Parallel cells 
were then treated with agonist and then fixed (internal fraction) or washed in 
PBS/EDTA and the fixed (Strip control).  A final set of cells were agonist treated, 
stripped and then returned to 37oC for one hour before fixation (recycled fraction).  All 
cells were then incubated under non-permeablising conditions with anti-mouse 
secondary labelled with AF594 as above.  Neurons were analysed by fluorescent 
microscopy (Zeiss) with images being taken at both red and green emissions with a 
constant gain, and fluorescent intensities recorded and analysed using ImageJ, and 
the ratio of 594 to 488 fluorescence recorded.   Internalisation was determined by the 
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following equation (1-(ratio 594:488 of internal fraction / ratio 594:488 of 100%) x 100.  
Recycling was determined by ((ratio 594:488 of recycled fraction - ratio 594:488 of 
strip) / (ratio 594:488 of 100% - ratio 594:488 of strip)) x 100.  For each condition, 6-
10 individual neurons were imaged and the 594:488 ratio determined. The mean ratios 
were then used to determine the internalised or recycled percentage for each n value 
2.12 Statistical analysis 
All analysis was carried out using GraphPad Prism software.  All n values refer to 
individual, independent experiments unless otherwise stated.  Unpaired t-test was 
used to compare colocalization data between treated and untreated conditions, and 
between receptor types.  Two-Way ANOVA was used to determine significant effects 





3.1 M2 Receptor undergoes lysosomal proteolysis in HEK 293 cells 
We initially investigated the downregulation of the M2 receptor (M2R) using an N-
terminally Flag-epitope-tagged human M2R (Hislop et al., 2009).  We first identified 
the endocytic fate of the M2R by the use of confocal microscopy and markers of 
distinct endocytic compartments.  M2R were transiently expressed in HEK 293 cells 
and incubated with fluorescently labelled M1 anti-flag antibody to label the surface 
receptor, before agonist treatment. In untreated cells, M2R staining is found 
exclusively at the plasma membrane with little observable constitutive internalization, 
or colocalization with any endocytic compartment (Supplemental Figure 1A-C). 
Following 30 minutes stimulation with 10 µM carbachol, M2R underwent translocation 
from the plasma membrane to discrete intracellular puncta.  These puncta ranged in 
size from small vesicles to much larger endosomes (Fig.1A, arrow), with many found 
colocalized with the Early Endosome Antigen 1 (EEA1) marker (Fig.1D).  After longer 
agonist treatment (120 and 180 minutes), M2R from the plasma membrane could be 
found colocalized with the late endosome marker Rab7 and also the lysosome marker 
LAMP1 (Fig.1B, C and D, Supplemental Fig.1F). These colocalization data suggest 
that the M2R might undergo rapid lysosomal proteolysis.  To investigate this we used 
immunoblotting of the N-terminal Flag epitope as a measurement of proteolysis (Hislop 
et al., 2004).  HEK 293 cells stably transfected with M2R were treated for increasing 
periods of time with 10 µM carbachol before lysis, separation by SDS-PAGE and 
detection by Western blotting using the anti-Flag antibody.  In untreated cells, the M2R 
resolved as heterogeneous immunoreactive bands (Fig.1E), similar to other GPCRs 
(Hislop et al., 2011, 2004).  The first of these (*) was a small band that resolved at the 
predicted weight of the M2R (~50kDa), a larger more prominent immunoreactive band 
was detected at ~60 kDa (#), and is likely the glycosylated monomeric surface 
expressed form of the M2R. Finally, a second highly prominent band was detected at 
>110 kDa, consistent with a dimeric form of M2R (‡, (Marsango et al., 2018)).  Agonist 
treatment with 10 µM carbachol saw a rapid loss of immunoreactivity of the monomeric 
species after 1-hour treatment, and an increase of immunoreactivity at the higher 
molecular weight species, which in turn decreased following longer treatments (3 – 5 
hours). Quantification of the whole lane revealed that there is a clear, agonist 
dependent loss of immunoreactivity with a t½ of 52 minutes (Fig.1F).  Pre-treatment 
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of M2R expressing cells with either chloroquine or Ammonium Chloride (Fig.1G) which 
inhibit lysosomal function, significantly prevented the agonist-induced loss of 
immunoreactivity (Two-Way ANOVA: chloroquine (F(3,24)=66.01, p<0.0001; 
Ammonium Chloride F(3,24)=23.63, p<0.0001; Fig.1H), indicating that M2R 
undergoes agonist induced lysosomal proteolysis. 
3.2 M2 Receptor proteolysis is regulated by ubiquitination and the ESCRT machinery. 
Lysosomal trafficking for a large number of membrane proteins requires ubiquitination 
of lysine residues within the intracellular domain (Raiborg and Stenmark, 2009).  
Protein ubiquitination promotes interaction with a number of ubiquitin-interacting 
proteins, including those that comprise the ESCRT complex, that target the protein to 
the lysosome (Katzmann et al., 2002; Raiborg et al., 2003), however, the role of 
ubiquitination and the ESCRT has remained less clear for GPCRs (Hislop et al., 2009; 
Marchese and Trejo, 2013).  To determine if ubiquitination and the ESCRT are 
responsible for regulating the lysosomal sorting of M2R, we initially investigated 
whether M2R colocalized with the core component of ESCRT 0, HRS (Bache et al., 
2003).  HEK 293 cells were transiently transfected with Flag-M2R and a low amount 
(100ng/9 cm2 cells) of GFP-HRS.  In untreated cells, M2R was observed at the plasma 
membrane (Fig. 2Ai), which redistributed to endosomal structures following agonist 
treatment (Fig. 2Aiv), which showed significant colocalization with HRS (Fig. 2iv-vi, 
Fig. 2B, t(53)=11.71, p=2.27x10-16). This data indicates that HRS and the ESCRT 
might play a role in regulating the endocytic trafficking of the M2R.  It was then 
investigated whether the colocalization with HRS was important for the proteolysis of 
M2R by the use of RNAi to reduce cellular levels of the HRS and the ESCRT I protein 
Tsg101 (Hislop et al., 2004).  Following transfection with RNAi oligonucleotides, M2R 
expressing cells were treated with 10 µM carbachol before analysis by immunoblotting 
(Fig. 2C and D). As before, control transfected cells, showed rapid M2R proteolysis, 
which was significantly inhibited by the knockdown of either HRS or Tsg101 (Two-Way 
ANOVA: HRS - F(3,32)=2.971, p=0.046; Tsg101 - (F(3,32)=3.709, p=0.021), 
indicating that a functional ESCRT complex is critical for sorting of the M2R to the 
lysosome. Interestingly, transfection with RNAi against Tsg101 also reduced the levels 
of HRS expression, although not to the extent of that caused by HRS siRNA, as 
previously reported (Gullapalli et al., 2006).  Although the mechanism that causes this 
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remains unknown, it is perhaps not surprising since Tsg101 and HRS form a complex 
(Lu et al., 2003).   
The involvement of the ESCRT complex is suggestive of direct ubiquitination being a 
requirement for M2R trafficking and downregulation, however, this may not be the 
case since other GPCRs have been shown to require functional ESCRT without 
needing receptor ubiquitination for lysosomal trafficking (Hislop et al., 2004).  This 
hypothesis was therefore investigated by determining whether the M2R underwent 
ubiquitination.  HEK 293 cells expressing M2R were transiently transfected with HA 
tagged-ubiquitin (Hislop et al., 2009; Marchese et al., 2003) and treated with 10 µM 
carbachol, before lysis, immunoprecipitation and analysis by immunoblotting with anti-
HA to detect ubiquitin.  Very little signal was seen in HEK 293 cells not expressing 
receptors (Fig.3B, 293 lane), however, a distinctive immunoreactive smear was 
detected in M2R expressing cells, even in the absence of agonist (Fig.3C). A small 
signal was detected at the monomeric receptor (*), with greater immunoreactivity at 
higher molecular weights.   The intensity of ubiquitination was mildly increased 
following receptor activation by carbachol, most noticeably at the monomeric species, 
(Fig.3B and D). Therefore, the M2R undergoes clear ubiquitination; however, this does 
not necessarily indicate a requirement for lysosomal trafficking (Hislop et al., 2004). 
To directly address this question we created a mutant M2R where all 28 intracellular 
lysine residues were mutated to arginine – M2R-0cK (Fig.3A), a strategy that has 
successfully been used to prevent ubiquitination of a number of GPCRs (Hislop et al., 
2011; Marchese and Benovic, 2001; Shenoy et al., 2001; Tanowitz and Von Zastrow, 
2002).  Indeed, this receptor showed no basal ubiquitination and no increase in 
ubiquitination following agonist activation (Fig.3B, C and D).  To further characterise 
the M2R-0cK, we first used immunofluorescent microscopy to follow its endosomal 
trafficking. Similarly, to the wild-type (WT) M2R, M2R-0cK was easily detected on the 
plasma membrane with little evidence of constitutive endocytosis (Supplemental Fig. 
2A-C).  Following agonist treatment, M2R-0cK was redistributed to endosomal 
compartments where colocalization was observed with EEA1, Rab7 and LAMP1 
(Supplemental Fig.2A-C).  Quantification of receptor endocytosis by flow cytometry 
revealed no difference between M2R and M2R-0cK (Supplemental Fig. D), indicating 
that the receptor can initiate endocytic trafficking identically to the WT receptor.  
Finally, we investigated whether the M2R-0cK is able to signal.  Since endogenous 
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muscarinic receptors make signalling difficult to interpret, we made DREADD 
mutations (Armbruster et al., 2007) in both the WT and M2R-0cK.  These two 
mutations confer on the receptor the ability to respond to clozapine-N-oxide (CNO), 
which does not activate other receptors.  Western blotting of phospho-ERK levels 
following agonist stimulation revealed no difference between the M2R and the M2R-
0cK in the response to CNO (Supplemental Fig. 2E).  Together these data suggest 
that the lysine mutations have not altered the function of the M2R.  Interestingly, upon 
quantification of M2R-0cK colocalization with endosomal markers, clear differences 
were observed between M2R and M2R-0cK (Supplemental Fig. 2F).  Most strikingly, 
colocalization with both Rab7 and LAMP1 was significantly reduced for M2R-0cK 
compared to M2R (Rab7; t(57)=15.16, p=1.08x10-21, DsRed-LAMP1; t(50)=15.07, 
p=2.27x10-20), suggesting that ubiquitination might play a role in the lysosomal 
trafficking of M2R, and subsequent proteolysis.   
To determine what role direct receptor ubiquitination had on M2R proteolysis, HEK 
293 cells stably expressing M2R-0cK were stimulated with carbachol before lysis and 
immunoblotting. Similar to the WT, M2R-0cK resolved as heterogenous 
immunoreactive bands, however, in stark contrast to the wild-type M2R, M2R-0cK 
showed no change in receptor levels even after extended agonist treatments (Two-
Way ANOVA: F(3,48)=5.98, p=0.0015, Fig. 3E and F).  We then used the gold 
standard method of measuring mAChR downregulation, that of radioligand binding to 
[3H]-Quinuclidinyl benzilate (QNB).  As with the previous assays, cells stably 
expressing the wild-type M2R show a clear agonist-induced reduction in specific [3H]-
QNB binding, consistent with a loss of receptors.  The t½ of 220 mins was slower than 
that seen for loss of epitope, consistent with the ligand binding site taking longer to be 
proteolyzed than the extracellular domain, but this rate was similar to that seen in other 
studies (Thangaraju and Sawyer, 2011).  In contrast however, cells expressing M2R-
0cK showed no decrease in [3H]-QNB binding (Two-Way ANOVA: F(3,30)=10.30, 
p<0.0001, Fig.3G). 
Finally, this critical result was verified by a biotin-protection-degradation assay to 
specifically follow the endocytic fate of the surface receptor (Thompson et al., 2014; 
Thompson and Whistler, 2011).  The M2R underwent clear endocytosis (Fig.3H – 30 
min) followed by a loss of signal after extended agonist treatments (Fig.3H and I), 
whereas the M2R-0cK underwent similar endocytosis but the endocytic pool was 
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maintained (Two-Way ANOVA: (F(2,18)=19.29, p<0.0001, Fig.3H and I). Together, 
these data show conclusively that ubiquitination of the M2R is required for agonist-
induced lysosomal trafficking and downregulation. 
 
3.3 Ubiquitin controls involution of the M2 Receptor 
It is hypothesised that ubiquitination of receptors targets them for lysosomal 
proteolysis by promoting the transfer of receptors from the limiting membrane of the 
endosome to intraluminal vesicles (a process termed involution).  This allows delivery 
of membrane cargo to the lumen of the lysosome following endosome fusion.  To 
determine whether ubiquitination is regulating sorting of M2R, we first utilised a 
previously described involution assay (Supplemental Fig. 3 (Henry et al., 2011)).  Both 
the M2R and M2R-0cK were C-terminally tagged in-frame with a pH-sensitive GFP 
variant – pHlorin.  These receptors were then co-expressed with the mCherry-Rab5-
Q79L constitutively active mutant to enlarge the endosomes to a point where the 
lumen can be clearly observed.  In these cells, any receptors that are found in the 
lumen of the endosome are not fluorescent, due to the quenching nature of the low 
endosomal pH.  The addition of chloroquine neutralises the luminal pH, revealing the 
presence of any tagged receptors within the lumen of the endosome (Fig.4A and B). 
Following agonist treatment for 90 mins, both the M2R and M2R-0cK can clearly be 
seen internalized from the plasma membrane onto the limiting membrane of the 
enlarged endosomal structures (Supplemental Fig.3B and C). Upon the addition of 
chloroquine, a large increase in intraluminal fluorescence was observed for the M2R 
(Fig.4A and C), consistent with a large proportion of receptor present within the lumen, 
whereas the M2R-0cK was largely excluded from the lumen (Fig.4B and C).  These 
data indicate that ubiquitination of the M2R promotes sorting to the lysosome by 
increasing involution. 
 
3.4 Ubiquitination of the M2 receptor controls post-endocytic sorting. 
The above data clearly show that preventing ubiquitination prevents M2R involution 
and subsequent proteolysis (Fig.4 and 3).  It has, however, previously been shown 
that involution does not necessarily determine whether a given GPCR undergoes 
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trafficking to the lysosome or is recycled to the plasma membrane (Henry et al., 2011; 
Hislop et al., 2011).    If a receptor is prevented from trafficking to the lysosome, it 
might be predicted that the receptor may undergo recycling instead; however, for many 
GPCRs this is not the case (Thompson and Whistler, 2011).  We used a previously 
described flow cytometry based assay to measure recycling of the endocytosed pool 
of receptors (Thompson et al., 2014).  Agonist treatment of both M2R and M2R-0cK 
caused a similar, substantial increase in fluorescence compared to control cells, 
consistent with internalization of both receptors (Fig.5A and B, 30 min bar).  Allowing 
the cells to recover for one hour in the absence of agonist showed only a small 
decrease in fluorescence of M2R expressing cells, indicating that the receptor was 
retained within the cell. This level of fluorescence was maintained for 3 hours after 
agonist removal, consistent with M2R not recycling and being trafficked to the late 
endosome.  Similarly, after one hour’s recovery, no reduction in fluorescence was 
seen in M2R-0cK expressing cells, however longer recovery periods (2 and 3 hours) 
showed a significant reduction in fluorescence (One-Way ANOVA: F(15)=5.94, 
p=0.01, Fig.5B) suggesting increased recycling of the M2R-0cK.  Quantification of 
recycling of the internalized fraction revealed a significant increase of M2R-0cK when 
compared to M2R (Two-Way ANOVA: F(2,18)=5.042, p=0.018, Fig.5C), albeit slower 
than that typically seen for rapidly recycling receptors (Lauffer et al., 2010; Temkin et 
al., 2011). 
We next used confocal microscopy to determine the route of M2R-0cK recycling.  HEK 
293 cells transiently expressing GFP-Rab11 and either M2R or M2R-0cK were fed M1 
antibody.  In cells not treated with agonist, both the M2R and M2R-0cK were found on 
the cell surface (Supplemental Fig. 4).  Following addition of 10 µM carbachol for 90 
minutes, both receptors underwent extensive internalization, however whereas the 
M2R was seen predominately in small vesicles, with a small number co-labelled with 
GFP-Rab11 (Fig.5D), M2R-0cK was seen to exhibit extensive colocalization with 
Rab11. Of particular note, the M2R-0cK was now found in a distinctive conglomerate 
of vesicles consistent with the perinuclear recycling compartment (Fig.5B, arrow).  
Quantification of colocalization showed a significant difference between M2R and 
M2R-0cK (t(77)=7.133, p=4.66x10-10, Fig. 5F), indicating a change in trafficking both 
qualitatively and quantifiably.  These data show that ubiquitination of the M2R targets 
the receptor for lysosomal proteolysis and in its absence the receptor undergoes slow 
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recycling through the Rab11 recycling pathway (Innamorati et al., 2001; Ullrich et al., 
1996; Wandinger-Ness and Zerial, 2014). 
 
3.5 Ubiquitination regulates post-endocytic sorting in Dorsal root ganglia 
The M2R has an important function in neurons where it is often found as a presynaptic 
auto-receptor or hetero-receptor (Lebois et al., 2018), and its downregulation has been 
implicated in a number of cognitive diseases (Dencker et al., 2012; Gibbons et al., 
2016; Lebois et al., 2018).  To determine if ubiquitin similarly regulates M2R trafficking 
in neurons, we used primary dissociated rat dorsal root ganglia neurons.  These were 
transfected with either Flag tagged M2R or M2R-0cK and endocytic trafficking 
measured by ratiometric fluorescence assay (Supplemental Fig. 5 (Tanowitz and von 
Zastrow, 2003; Yu et al., 2010)).  Under visual inspection, the M2R underwent 
endocytosis with many puncta seen in both the cell body and neurites, and the 
prevention of ubiquitination had no effect on this (Fig. 6A and B). Quantification 
revealed that both receptors underwent similar amount of internalization (Fig. 6C). In 
contrast, however, recycling was greatly increased by the prevention of ubiquitination.  
WT M2R underwent limited recycling (~30%) whereas M2R-0cK was recycled 
significantly more (~70%, t(4)=2.652, p=0.0284) after one hour following agonist 
washout (Fig. 6D).  Finally, the M2R-0cK was again found to be colocalized with Rab11 
(Fig. 6F), whereas only limited colocalization is seen with the WT M2R, consistent with 
the small amount of recycling observed (Fig. 6E).  Together these data show that post-
endocytic sorting of the M2 receptor is controlled by ubiquitination, a mechanism 
maintained in primary neurons. 
 
4. Discussion 
The Gi-coupled M2R plays important roles in the CNS where it is a critical presynaptic 
receptor that reduces neurotransmitter release, and can be found within the 
hypothalamus, hippocampus and neocortex (Lebois et al., 2018; Thomsen et al., 
2018).  The disruption of M2R signalling has important consequences within the CNS.  
M2R knockout mice show a number of cognitive deficits including working memory 
and spatial memory, and decreases in M2R levels have been shown in the cortex of 
19 
 
Alzheimer’s patients as well as those with bipolar disorder (Gibbons et al., 2016; Kruse 
et al., 2014; Scarr, 2012; Thomsen et al., 2018).  It is therefore critical for both 
understanding of the progression of these diseases and also the development of 
therapeutics to identify the molecular mechanisms regulating this process of M2R 
downregulation.  Here we identify, for the first time, receptor ubiquitination as the 
critical regulator of M2R downregulation. 
The model for ubiquitin dependent sorting to the lysosome has predominantly been 
based around early studies in yeast, where cargo destined for the vacuole undergoes 
ubiquitination of lysine residues which allows interaction with the ESCRT complex of 
ubiquitin interacting proteins (reviewed in (Haglund and Dikic, 2012; Katzmann et al., 
2002; Raiborg and Stenmark, 2009; Saksena et al., 2007).  The ESCRT complex has 
a dual role in both the binding and sorting of ubiquitinated cargo and also the formation 
of multivesicular bodies by the process of involution (Schoneberg et al., 2017).  The 
combined function of the ESCRT both sorts and removes ubiquitinated cargo from the 
endosome membrane, translocating it into the endosome lumen, where it is accessible 
to lipases and proteases following fusion with the vacuole.  The same process has 
been described for the lysosomal sorting of tyrosine kinase receptors in mammalian 
cells (Eden et al., 2009; Haglund and Dikic, 2012; Raiborg et al., 2003; Razi and Futter, 
2006; Tomas et al., 2014), however, GPCR sorting appears to be more complicated 
process.  Although it has been clear for many years that ubiquitin plays a central role 
in the downregulation of many GPCRs (Jacob et al., 2005; Marchese and Benovic, 
2001; Martin et al., 2003; Shenoy et al., 2001), the specific action and requirement 
remains enigmatic and can vary between different receptors.  Indeed, although clearly 
involved in the regulation of GPCR proteolysis, the actual role of ubiquitin in 
determining endocytic fate is far more complicated.  For example, early studies into 
the downregulation of CXCR4 showed a clear requirement for both ubiquitination and 
the ESCRT complex and disruption of this process prevented sorting to the lysosomal 
compartment (Bhandari et al., 2009; Marchese et al., 2003; Marchese and Benovic, 
2001).  Similarly, PAR2 and NK1R also appear to be regulated by both direct 
ubiquitination and the ESCRT machinery, however, whether this is linked to involution 
remains unknown (Cottrell et al., 2006; Hasdemir et al., 2009, 2007; Jacob et al., 
2005).  In contrast, both the mu and delta opioid receptors (MOR and DOR 
respectively) undergo clear ubiquitination following agonist activation, however, this 
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process controls the involution into multivesicular bodies, and not the sorting to the 
lysosome (Henry et al., 2011; Hislop et al., 2011, 2009; Tanowitz and Von Zastrow, 
2002), which appears to be governed by a ubiquitin-independent process, such as an 
interaction with GASP proteins (Thompson et al., 2007; Whistler et al., 2002).  Finally, 
the PAR1 receptor is sorted to the lysosomes independently of both ubiquitination and 
the ESCRT components HRS and Tsg101 (Dores et al., 2016, 2012; Gullapalli et al., 
2006).  Despite the undoubted importance of how GPCRs undergo downregulation, 
the relevance of the ubiquitin-ESCRT model for this class of receptors remains under 
investigated.  
Here we show that the M2R undergoes rapid sorting to the lysosome and this process 
is regulated by both ubiquitin and the ESCRT complex. Knockdown of both ESCRT 0 
(HRS) and ESCRT I (Tsg101) reduced M2R proteolysis, and while it is possible that 
the observed effect of Tsg101 caused by a reduction of HRS (see Fig. 2D), we find 
this unlikely, since similar effect was not seen previously with the DOR, whose 
proteolysis is unaffected by Tsg101 RNAi (Hislop et al., 2004).  Furthermore, we 
clearly identify that for the M2R, ubiquitination drives involution into multivesicular 
bodies, suggesting that involution is the primary mechanism by which M2R is sorted 
away from recycling pathways and towards the lysosome.  Although consistent with 
the ubiquitin-ESCRT model described above, this would be the first demonstration of 
ubiquitin-dependent involution regulating sorting of a GPCR.  Other GPCRs have been 
shown to require both ubiquitin and ESCRT machinery for lysosomal sorting 
(Hasdemir et al., 2007; Jacob et al., 2005; Marchese et al., 2003), however, the role 
of involution in the sorting of these receptors has largely been overlooked.  Further, 
the time course of downregulation for those GPCRs regulated by ubiquitin is 
significantly slower than that shown for the M2R, raising the question of why there is 
such rapid involution and lysosomal sorting of the M2R?  In addition to targeting 
receptors for degradation, rapid involution has also been proposed switch off signalling 
of tyrosine kinase receptors like the EGFR, by insulating it from cytosolic signalling 
cascades (Eden et al., 2009; Kostaras et al., 2013).   It is interesting to speculate that 
a similar function may be occurring for the M2R.  For GPCRs in general, there is 
renewed interest in signalling from the endosome, both through G-proteins and G-
protein-independent pathways (Irannejad and von Zastrow, 2014; Peterson and 
Luttrell, 2017; Vilardaga et al., 2014).  Although there is currently little evidence for 
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endosomal signalling of the M2R, it is interesting to note that M2R does form stable 
endosomal complexes with arrestin (Mosser et al., 2008), in which regard it is similar 
to both the Angiotensin II receptor and Vasopressin 2 receptor, both of which do exhibit 
extensive endosomal signalling (Jean-Charles et al., 2016; Peterson and Luttrell, 
2017; Shenoy et al., 2009; Vilardaga et al., 2014).  If such signalling is also observed 
for the M2R, then ubiquitin-ESCRT mediated involution would allow its rapid cessation, 
and offer a potential explanation for this rapid process, not seen in other GPCRs.   
Interestingly, stable arrestin-receptor complexes, as seen for the M2R, have been 
suggested to be regulated by the ubiquitination state of arrestin, which controls both 
signalling and trafficking of the receptor (Berthouze et al., 2009; Shenoy and Lefkowitz, 
2003).  Indeed, the ubiquitination of arrestin has previously been shown to be a factor 
in controlling M2R downregulation (Mosser et al., 2008).  The role of arrestin in 
downregulation, was not investigated in the current study, but it is worth noting that 
arrestins have been shown to interact with ESCRT  and modulate the downregulation 
of the CXCR4 chemokine receptor, another GPCR which is predominantly sorted 
through ubiquitination (Bhandari et al., 2007; Malik et al., 2012). 
One critical finding of this study is that the disruption of M2R ubiquitination not only 
prevented its lysosomal sorting, but also rerouted trafficking through Rab11 positive 
endosomes to be returned to the plasma membrane.  These findings were somewhat 
surprising, since the lysosomal trafficking of rapidly degraded GPCRs (< 2hours) 
typically requires ubiquitin-independent processes (Whistler et al., 2002), and 
preventing ubiquitination does not therefore, cause a rerouting to the recycling 
pathway (Henry et al., 2011), although this has been partially observed for receptors 
that undergo lysosomal targeting with far slower kinetics (PAR2 and NK1, (Cottrell et 
al., 2006; Jacob et al., 2005)).  This is an important distinction between M2R and 
previously described receptors such as the DOR and MOR, since it implies that the 
targeting of the ubiquitination process is a viable strategy for preventing 
downregulation and maintaining surface receptor number.  The loss of functional 
receptors has, for some time, been a stumbling block for the use of agonists as 
therapeutics, as this can lead to pharmacological tolerance, reducing their clinical 
effectiveness.  Further, the loss of functional muscarinic receptors is observed in a 
range of mental health disorders (Dencker et al., 2012; Lebois et al., 2018; Scarr, 
2012).  Combined, these data identify the downregulation of muscarinic acetylcholine 
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receptors as an important regulatory mechanism in disease states, and that preventing 
downregulation by targeting receptor ubiquitination has potential to reduce both 
tolerance and also reverse the symptoms of these disorders. 
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Figure 1 – M2R undergoes lysosomal proteolysis 
A-C) HEK 293 cells were transiently transfected with N terminally Flag-tagged M2R 
(F-M2R) and the indicated marker and plated on coverslips. Cells were fed with AF-
M1 antibody (magenta) and treated with carbachol (10 µM) as indicated, before fixing 
and staining. A) M2R-AF568 (magenta, i) and cells stained with anti-EEA1 (green, ii). 
B) M2R-AF-568 (magenta, i) and GFP-Rab7 (green, ii). C) M2R-AF488 (magenta, i) 
and DsRed-LAMP1 (green, ii).  Dotted lines show the outline of the cells, arrows show 
areas of colocalization (white).  D) Quantification of colocalization using Manders’ 
coefficient.  Graph shows colocalization with the indicated marker following agonist 
treatment for the indicated time (EEA1, n=50 cells; GFP-Rab7, n=40 cells; LAMP1, 
n=38 cells, images taken from 3-4 independent experiments). E-F) HEK 293 stably 
expressing F-M2R were treated for the indicated time with 10µM carbachol, before 
lysis and SDS-PAGE.  Shown is a representative anti-Flag Western blot, with 
quantification by densitometry (mean ± SEM, n=7, t½ determined by non-linear 
regression assuming a single exponential).  G-H) F-M2R cells were pre-treated for 30 
mins with chloroquine or Ammonium Chloride before treated for the indicated time with 
10µM carbachol and Western blotting.  Shown are representative anti-Flag Western 
blots, quantified by densitometry (mean ± SEM, n=4. Two-Way ANOVA: chloroquine; 
F(3,24)=66.01, p<0.0001; Ammonium Chloride; F(3,24)=23.63, p<0.0001, post-test 
statistics shown on graph, H). 
Figure 2 – ESCRT is required for M2R proteolysis 
A-B) HEK 293 cells were transiently transfected with F-M2R (1µg) and GFP-HRS 
(100ng) and plated on coverslips. Cells were fed with AF-568-M1 antibody (magenta, 
i and iv) for 30 mins before left untreated or treated with carbachol (10µM) for 30 mins, 
followed by fixation in 4% formaldehyde, and analysed by confocal microscopy. B 
shows quantification of colocalization using Manders’ coefficient (unpaired t-test: 
t(53)=11.71, p=2.27x10-16. C-D) HEK 293 stably expressing F-M2R were transfected 
with the indicated siRNA, replated and 72 hours later treated for the indicated time 
with 10µM carbachol, before lysis and SDS-PAGE.  Shown is a representative anti-
Flag Western blot (D), with quantification by densitometry (mean ± SEM, n=5. Two-
Way ANOVA: HRS; F(3,32)=2.971, p=0.046, TSG101; F(3,32)=3.709, p=0.021, 
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Bonferroni post hoc test shown on graph, D). Blots were stripped and reprobed with 
anti-HRS or anti-Tsg101.   
Figure 3 – Ubiquitination is required for M2R proteolysis 
A) Schematic representation of the M2R indicating the position of the 28 lysine 
residues replaced with arginine. B-D) HEK 293 calls stably transfected with F-M2R or 
F-M2R-0cK, were transiently transfected with HA-Ubiquitin, before treatment with 
10µM carbachol for the indicated time, and lysis (see method) and SDS-PAGE.  
Shown is a representative anti-HA Western blot.  These were quantified (mean ± SEM, 
n=4), to show the level of ubiquitination in unstimulated cells compared to receptor null 
cells (C, One-Way ANOVA: F(3)=9.299, p=0.065, C), and the agonist induced 
ubiquitination effect compared to untransfected cells (D mean ± SEM, n=4, Two-Way 
ANOVA: F(4,30)=0.23, p=0.917).  E-F) M2R or M2R-0cK cells were treated with 10µM 
carbachol for the indicated time before lysis and Western blotting. Shown is a 
representative anti-Flag Western blot (E), and quantification by densitometry (mean ± 
SEM, n=7. Two-Way ANOVA: F(3,48)=5.978, p=0.0015, Bonferroni post hoc test 
shown on graph F).  G) M2R or M2R-0cK cells were treated with 10µM carbachol for 
the indicated time before washing and freeze-thaw in PBS followed by radioligand 
binding with [3H]-QNB (mean ± SEM, n=6. Two-Way ANOVA: F(3,30)=10.3, p<0.0001. 
Bonferroni post hoc test shown on graph, G).  H-I) Biotin-Protection assay of M2R and 
M2R-0cK to show the fate of surface receptors. Shown is a representative blot probed 
with streptavidin-HRP to label biotinylated proteins (H). 100% lane is total surface 
receptor, strip represents efficiency of strip, non-treated is cells incubated in the 
absence of agonist.  Blots were quantified by densitometry (mean ± SEM, n=4. Two-
Way ANOVA: F(2,18)=19.29, p<0.0001, Bonferroni post hoc test values shown)   
Figure 4 – Ubiquitination regulates the involution of the M2R. 
HEK 293 cells were transiently transfected with mCherry-Rab5-Q79L and ether F-
M2R-SEP (A) or F-M2R-0cK-SEP (B) and plated on coverslips. Cells were then 
treated with carbachol (10µM) for 90 mins and imaged by spinning disc confocal 
microscopy. Cells were imaged for 1 minute, before chloroquine (500 µM) was added. 
Shown is a representative image series of a single enlarged endosomes (scale bar = 
5 µM, showing the increase in intraluminal fluorescence, following neutralization of the 
endosome lumen. Data is illustrative of four independent days of experimentation.  The 
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increase in luminal fluorescence was then quantified (M2R, n=12 cells, 50 endosomes 
and M2R-0cK, n=14 cells, 47 endosomes, unpaired t-test;  t(84)=9.07, p=4.3x10-14). 
Figure 5 – Ubiquitination regulates endocytic sorting of the M2R. 
HEK 293 cells were transiently transfected with F-M2R (A) or F-M2R-0cK (B), and 
analysed by FACS for recycling. Cells were incubated with anti-Flag-AF647 before 
agonist treatment with carbachol for 30 min.  Cells were washed with PBS-EDTA to 
remove remaining surface staining and then incubated at 37oC for 60, 120 or 180 
minutes, and remaining fluorescence measured (mean ± SEM, n=4. One-Way 
ANOVA: M2R - F(15)=1.829, p=0.196; M2R-0cK – F(15)=5.94, p=0.01, post-hoc tests 
shown on graph B). The extent of recycling (C) was determined by the amount of 
fluorescence caused by internalization remaining following the recovery period (mean 
± SEM, n=4. Two-Way ANOVA: F(2,18)=5.042, p=0.018, with post-hoc test values 
shown). D and E) HEK 293 cells were transiently transfected with F-M2R (D) or F-
M2R-0cK (E) and GFP-Rab11 (ii) and plated on coverslips. Cells were fed with AF-
568-M1 antibody (magenta, i) and treated with carbachol (10 µM) for 90 mins, before 
fixing.  Dotted lines show the outline of the cell and arrows indicate the Rab11 +ve 
recycling compartment. F) Colocalization was quantified using Manders’ coefficient 
(M2R, 39 cells, M2R-0cK, 40 cells, unpaired t-test: t(77)=7.133, p=4.66x10-10). 
Figure 6 – Ubiquitination regulates the endocytic sorting of M2R in primary cultured 
DRGs. 
DRG cultures transfected with F-M2R (A) or F-M2R-0cK (B) were fed with anti-FLAG-
M1-AF-488 (green) before agonist treatment (Aii and Bii) and fixation under non-
permeabilizing conditions.  Cells were then stained with anti-mouse-AF-594, to label 
any antibody still on the cell surface surface (magenta), scale bars represent 10 µM.  
Ratiometric analysis was then used to determine internalisation (C) and Recycling (D) 
(Yu et al., 2010), (mean ± SEM, n=3, unpaired t-test t:  Internalization – t(4)=0.073, 
Recycling – t(4)=2.652).  E and F) DRG cells were fed M1-568, treated with carbachol 
for 90 minutes, before fixing and staining with anti-Rab11 antibody.  Images show 
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Supplemental Figure Legends 
Supplemental Figure 1 – Analysis of M2R colocalization. 
A-C) Shows the untreated conditions corresponding to Figure 1. HEK 293 cells were 
transiently transfected with N terminally Flag-tagged M2R (M2R) alone (A) or with the 
indicated marker (B and C) and plated on coverslips. Cells were incubated with AF-
M1 antibody (magenta, i) for 60 mins before fixing. A) M2R-AF568 (magenta, i) and 
cells stained with anti-EEA1 (green, ii). B) M2R-AF-568 (magenta, i) and GFP-Rab7 
(green, ii). C) M2R-AF488 (magenta, i) and DsRed-LAMP1 (green, ii).  Dotted lines 
show the outline of the cells. D) Quantification of colocalization by Manders’ coefficient 
and statistical analysis using unpaired t-test with Welch correction for unequal 
variance, between untreated (0) and carbachol treated conditions.  EEA1 – 
t(55)=17.02, p=1.03 x10-23, GFP-Rab7 – t(57)=15.16, p=1.08x10-21, DsRed-LAMP1 – 
t(50) = 15.07, p=2.27x10-20.  
Supplemental Figure 2 – Characterization of M2R-0cK 
A-C) HEK 293 cells were transiently transfected with N-terminally Flag-tagged M2R-
0cK and the indicated marker and plated on coverslips.  Cells were incubated at 37oC 
with AF-labelled M1 anti-Flag, for 30 minutes before agonist treatment with 1 µM 
carbachol for the indicated times before fixation.  A) M2R-0cK-AF568 (magenta, i and 
iv) and cells stained with anti-EEA1 (green, ii and v). B) M2R-0cK-AF568 (magenta, i 
and iv) and GFP-Rab7 (green, ii and v). C) M2R-0cK-AF488 (magenta, i and iv) and 
Ds-Red-LAMP1) (green, ii and v).  Dotted lines show the outline of the cell.  D) HEK293 
cells were transiently transfected with F-M2R or F-M2R-0cK and incubated with anti-
Flag-AF647 for 30 mins before addition of 1µM carbachol for the indicated time.  Cells 
were then washed and incubated in PBS/EDTA to remove any antibody bound to 
surface receptor, and remaining fluorescence measured by flow cytometry.  
Internalization between receptors was unchanged (mean ± SEM, n=4. Two-Way 
ANOVA: F(3,24)=0.153, p=0.927).  E) DREADD mutations (Y104C, A193G) were 
introduced into the M2R and M2R-0cK as designed by Armbruster et al., 2007. Stable 
cell lines expressing the receptors were then treated for 7 minutes with the indicated 
concentration of Clozapine-N-oxide, before lysis and analysis by SDS-PAGE, and 
probed for phospho-ERK.  Shown is a representative immunoblot (n=2), indicating no 
difference in the signalling of the ‘WT’ or 0cK receptors. F) Quantification of 
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colocalization by Manders’ coefficient, and comparison with similarly treated cells 
expressing M2R as described in Figure 1, using unpaired t-test.  Colocalization of M2R 
(50 cells) or M2R-0cK (32 cells) with EEA1 after 30 mins carbachol – t(79)=3.18, 
p=0.004. Colocalization of M2R (40 cells) or M2R-0cK (43 cells) with GFP-Rab7 after 
120 mins carbachol – t(81)=5.864, p=9.4x10-8. Colocalization of M2R (38 cells) or 
M2R-0cK (38 cells) with DsRed-LAMP1 after 180 mins carbachol – t(69)=5.995, 
p=2.7x10-5. 
Supplemental Figure 3 – lysine mutation prevents involution of the M2R. 
Schematic of assay and quantification as previously described (Henry et al., 2011).  
HEK 293 cells were transiently transfected with mCherry-Rab5-Q79L and ether F-
M2R-SEP (B) or F-M2R-0cK-SEP (C) and plated on coverslips. Cells were then 
treated with carbachol (10µM) for 90 mins before imaging by spinning disc confocal 
microscopy. Cells were imaged for 1 minute and then 500 µM chloroquine was added, 
and the cells imaged for a further 5 minutes. Shown is a representative image series 
(four independent experiments) of the whole cell, and the enlarged endosome inset, 
showing the increase in intraluminal fluorescence, for M2R (B) and M2R-0cK (C). The 
chloroquine induced fluorescence was then quantified by taking the mean 
fluorescence of the endosome immediately after chloroquine addition (6 frames) and 
after 5 mins (6 frames) and expressed as a fold increase.  
Supplemental Figure 4 – Surface expression is unchanged by coexpression of GFP-
Rab11. 
HEK293 cells were transfected with GFP-Rab11 and either M2R or M2R-0cK, and 
then plated onto coverslips.  Cells were incubated with AF568 labelled M1 anti-Flag 
for 60 minutes at 37oC, before fixation and mounting for confocal analysis. 
Supplemental Figure 5 – Ratiometric internalization of M2R in DRG cells 
DRG cultures transfected with F-M2R were fed with anti-FLAG-M1-AF-488 (green) 
and left either untreated (i) or treated for 30 minutes with 1 µM carbachol (iii).  Cells 
were then fixed with 4% paraformaldehyde under non-permeabilising conditions, and 
then incubated with anti-mouse secondary conjugated to AF594, which only label 
antibody still on the surface of the cell (ii and iv).  The ratio of 488 to 594 fluorescence 
was then measured by fluorescent microscopy for each condition, and then the ratio 
3 
 
measured in the agonist treated condition expressed as a percentage of the ratio in 
the untreated condition to give the internalized fraction (Yu et al., 2010).  
Supplemental Figure 6 
A-C) Original and uncropped anti-Flag Western blots corresponding to Figure 1E (first 
four lanes on left side) and 1G  
Supplemental Figure 7 
A-D) Original and uncropped Western blots corresponding to Figure 2D.  A) is the anti-
Flag blot, B) anti-HRS, C) anti-Tsg101 and D) is anti-GAPDH 
Supplemental Figure 8 
A-D) Original and uncropped Western blots corresponding to Figure 3.  A) is the anti-
HA blot corresponding to Figure 3B.  B) is the anti-Flag blot of Figure 3E.  C and D) 
are the biotin-streptavidin blots of Figure 3H. C shows M2R and D shows M2R-0cK 
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